GUD:CA:TSX-Knight Therapeutics Inc. (CAD)

EQUITY | Drug Manufacturers - Specialty & Generic | Toronto Stock Exchange

Last Closing

CAD 5.42

Change

+0.05 (+0.93)%

Market Cap

CAD 1.31B

Volume

0.07M

Analyst Target

CAD 8.74
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Knight Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

+0.09 (+0.80%)

CAD 3.94B
TLRY:CA Tilray Inc

+0.08 (+3.94%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.02 (-0.87%)

CAD 1.61B
CRON:CA Cronos Group Inc

-0.01 (-0.35%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

+0.78 (+6.66%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.07 (-1.67%)

CAD 0.60B
AOV:CA Amotiv Limited

-0.01 (-0.18%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

N/A

CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

+0.01 (+0.07%)

CAD 0.38B
ACB:CA Aurora Cannabis Inc

+0.02 (+0.30%)

CAD 0.36B

ETFs Containing GUD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.50% 32% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.50% 32% F 68% D+
Trailing 12 Months  
Capital Gain -3.04% 50% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.04% 50% F 14% F
Trailing 5 Years  
Capital Gain -28.59% 86% B+ 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.59% 86% B+ 13% F
Average Annual (5 Year Horizon)  
Capital Gain -2.62% 55% F 16% F
Dividend Return -2.62% 55% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.03% 100% F 56% F
Risk Adjusted Return -17.46% 45% F 13% F
Market Capitalization 1.31B 74% C 61% D-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 74.10 53% 13%
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital 1.47% 74% 34%
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector